Home › NDC Lookup › RxCUI directory › RxCUI 2262288

Simethicone 25 MG/ML Oral Suspension — RxCUI 2262288

RxNorm drug concept · Semantic clinical drug
RxCUI 2262288 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 3 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2262288
Official nameSimethicone 25 MG/ML Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known assimethicone 125 MG per 5 ML Oral Suspension; simethicone 125 MG in 5 mL Oral Suspension
FDA products mapped2
Package NDCs mapped3
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Simethicone: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Simethicone works to relieve the uncomfortable pressure, bloating, and full or stuffed feeling that comes from trapped gas in your stomach or intestines. It's used when gas builds...
  • What exactly does simethicone do for gas?
  • Yes — there are infant-specific simethicone products, like Mylicon Infants Gas Relief and similar infant drops, designed just for babies. They're used to relieve gas discomfort tha...
  • Can I give simethicone drops to my baby?
📖 Read our full Simethicone guide →

🕸️ Concept Web — How Simethicone 25 MG/ML Oral Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Simethicone 25 MG/ML Oral Suspension RxCUI 2262288

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Simethicone 9796
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Simethicone Oral Suspension 373883
    • Simethicone Oral Liquid Product 1158750
    • Simethicone Oral Product 1158751
    • Oral Suspension 316969
    • Oral Liquid Product 1151137
    • Oral Product 1151131
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Simethicone 25 MG/ML 334987

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Simethicone 25 MG/ML SCDC · 334987
  • Simethicone Oral Suspension SCDF · 373883
  • Simethicone Oral Liquid Product SCDG · 1158750
  • Simethicone Oral Product SCDG · 1158751

📦 FDA Products & Package NDCs

2 products · 3 package NDCs
3 package NDCs map to RxCUI 2262288 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
55505-0225-36 237 mL in 1 BOTTLE (55505-225-36) EXTRA STRENGTH gas relief KRAMER LABORATORIES 2023-11-03
55505-0225-83 2 BOTTLE in 1 PACKAGE (55505-225-83) / 237 mL in 1 BOTTLE EXTRA STRENGTH gas relief KRAMER LABORATORIES 2025-05-01
68163-0700-08 237 mL in 1 BOTTLE (68163-700-08) EXTRA STRENGTH gas relief Raritan Pharmaceuticals Inc 2020-08-26
Observed labelers: KRAMER LABORATORIES (2) · Raritan Pharmaceuticals Inc (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.